Stock Report

All about this stock under one free report Last Updated: 31-Aug-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

MaxCyte (MXCT) Key Ratios

Stock Card factsheet share-fund-plan-icon

$1.22

up-down-arrow $-0.06 (-4.69%)

As on 28-Aug-2026 16:01EDT

Market cap

info icon

$126 Mln

Revenue (TTM)

info icon

$31 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

0.8

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -24.66 -14.53 -13.15 -8.61 1.46
EBIT -- -- 40.23 5.66 -20.13
Net Profit -86.82 28.19 20.41 -3.16 -157.44
EPS -86.91 28.47 21.12 -1.74 -15.11
Book Value -- -- -18.09 -13.47 30.18
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-25Dec-24
EBIT-Margin info -111.09-87.89-86.19-135.14-106.29
Net Margin info ---53.44-114.77----
Return on equity info -19.32-15.99-21.58-23.63-18.73
Return on Capital info -17.80-14.90---21.58-17.28
Return on Assets info -16.68-13.93-13.27-20.20-16.17
Debt to Equity (x) info ----0.000.100.09

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
MaxCyte (MXCT)
--
-21.58
-17.28
-14.56
-8.75
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-21.58

Lower than Peers by 26.53

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
MaxCyte (MXCT)
-21.58
-23.63
-18.73
-15.60
-9.12
Peer Median
4.94
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-13.27

Lower than Peers by 15.72

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
MaxCyte (MXCT)
-13.27
-20.20
-16.17
-13.67
-8.26
Peer Median
2.45
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

-86.19

Lower than Peers by 94.66

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
MaxCyte (MXCT)
-86.19
-135.14
-106.29
-91.85
-52.97
Peer Median
8.47
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

-114.77

Lower than Peers by 119.44

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
MaxCyte (MXCT)
-114.77
-135.14
-106.29
-91.85
-49.05
Peer Median
4.68
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

0.00

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
MaxCyte (MXCT)
0.00
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

-13.15

Lower than Peers by 21.64

Year on year growth in net sales

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
MaxCyte (MXCT)
-13.15
-0.15
-0.06
-0.07
0.31
Peer Median
8.49
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

40.23

Higher than Peers by 29.58

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
MaxCyte (MXCT)
40.23
-8.71
-8.26
-61.76
-29.97
Peer Median
10.65
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

20.41

Higher than Peers by 6.85

Year on year growth in profit after tax

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
MaxCyte (MXCT)
20.41
-8.71
-8.26
-60.89
-23.52
Peer Median
13.55
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

21.12

Higher than Peers by 0.61

Year on year growth in earnings per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
MaxCyte (MXCT)
21.12
-0.07
-0.07
-0.58
-0.22
Peer Median
20.51
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

-17.09

Lower than Peers by 24.10

Year on year growth in book value per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
MaxCyte (MXCT)
-17.09
--
--
--
--
Peer Median
7.01
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
MaxCyte (MXCT)
--
0.10
0.09
0.08
0.06
Peer Median
0.40
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.01

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
MaxCyte (MXCT)
0.01
0.01
0.00
0.00
0.00
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

12.26

Higher than Peers by 9.43

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
MaxCyte (MXCT)
12.26
8.30
10.88
10.65
16.35
Peer Median
2.83
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

11.47

Higher than Peers by 9.42

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
MaxCyte (MXCT)
11.47
7.77
10.32
9.97
15.80
Peer Median
2.05
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

--

--

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
MaxCyte (MXCT)
--
--
--
--
-184.74
Peer Median
4.96
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

12.63

Lower than Peers by 3.83

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
MaxCyte (MXCT)
12.63
10.61
12.12
13.99
25.25
Peer Median
16.46
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.12

Lower than Peers by 0.39

Sales / Average Total Assets

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
MaxCyte (MXCT)
0.12
0.15
0.15
0.15
0.16
Peer Median
0.50
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
MaxCyte (MXCT)
--
45.26
49.45
74.99
74.48
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
MaxCyte (MXCT)
--
483.15
543.84
801.44
493.84
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
MaxCyte (MXCT)
--
80.98
54.04
39.86
75.67
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
MaxCyte (MXCT)
--
447.44
539.25
836.57
492.66
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
MaxCyte (MXCT)
--
-3.70
-10.62
-12.85
-23.66
Peer Median
44.46
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

0.83

Lower than Peers by 2.96

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
MaxCyte (MXCT)
0.83
0.96
2.11
2.10
2.20
Peer Median
3.79
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
MaxCyte (MXCT)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

-11.07

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
MaxCyte (MXCT)
-11.07
-2.02
-8.26
-10.01
-16.69
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

126

Lower than Peers by 414

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
MaxCyte (MXCT)
126
--
--
--
--
Peer Median
540
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...